StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

369 Study Matches

MT2019-01: Adrenoleukodystrophy National Registry Study (ALD) and Biobank

The purpose of this research to enhance our understanding of adrenoleukodystrophy ALD and study biospecimens such assaliva, blood, urine and stool to identify potential biomarkers for early identification of dise. We invite people who have or are at risk to have ALD, including females who are known or at risk carriers of the mutation for ALD, to help us learn more.

Ashish Gupta
Not specified
This study is NOT accepting healthy volunteers
STUDY00003605
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• age 0 to 100
• patient or family member diagnosed with ALD (confirmed by positive VLCFA testing and/or genetic mutation
• patient or family member with known or presumed mutation with ALD based on pedigree or confirmed mutation in ABCD1 gene
• living in the United States and territories
Exclusion Criteria:

• have undergone BMT or other cellular therapy
• not fluent in English who are unable to consent in-person
• people who are unable to read or write
Rare Diseases
Adrenoleukodystrophy, ALD, Cerebral Adrenoleukodystrophy
I'm interested
Share via email
See this study on ClinicalTrials.gov

Building Resilience in Adrenoleukodystrophy with Imaging and Neuropsychology (BRAIN)

This study is about a genetic condition called Adrenoleukodystrophy (ALD). The first goal of this study is to understand more about how ALD affects a child’s brain and development in childhood as they take part in medical care and monitoring. This is important to identify the optimal ways to detect and treat manifestations of ALD such as cerebral ALD. The second goal is to learn about how ALD affects caregivers, so that clinicians can offer better support to families in the future. We will also have healthy comparisons to help to learn more about the condition (ALD) being studied, by comparing the information collected to a child without the condition.

Rene Pierpont
Up to 18 years old
This study is also accepting healthy volunteers
STUDY00016246
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 3 to 15 years old
• male
• diagnosis of ALD either at-risk for ALD: patients with genetically or biochemically-diagnosed ALD who currently have no evidence of cerebral disease on MRI and b) Cerebral ALD: boys with the cerebral form of ALD who underwent or are undergoing evaluation or treatment for this condition and have early stage disease
• for healthy volunteers: males between 3 and 15 years old
Exclusion Criteria:

• girls are excluded because this is a genetic disease that only males get
• history of a genetic, neurological, or neurodevelopmental disorder affecting brain development
• history of significant brain insult, infection or injury
Brain & Nervous System, Children's Health, Rare Diseases
Healthy control, children, pediatrics, adolescents
I'm interested
Share via email

CONQUER Protocol Number 001: COllaborative, National QUality and Efficacy Registry for Tracking Disease Progression in Systemic Sclerosis (Scleroderma) Patients (CONQUER)

The purpose of this study is to develop a cohort of patients with early scleroderma, and to collect data on clinical outcomes, radiological tests, laboratory tests and to obtain biological specimens for testing.We hope to explore medical care and the impact of SSc on patients' daily lives through various questionnaires that will be collected during study participation. By looking at all of the areas mentioned, we hope to find out information about SSc that will help treat future patients, develop new treatments, and work towards a cure.

Jerry Molitor
18 years and over
This study is NOT accepting healthy volunteers
STUDY00014622
Arthritis & Rheumatic Diseases
Clinics and Surgery Center (CSC)
I'm interested
Share via email

EPI-MINN: Targeting Cognition and Motivation in Coordinated Specialty Care for Early Psychosis: A National Comparison Study

This is a study enrolling patients receiving care for early psychosis across the United States. Participants will be randomly assigned to one of two groups. The first group will use two mobile apps, computerized brain training and a motivational smart phone app, for a period of 12 weeks. The other group will participate in their regular clinical care. There will be 4 study timepoints: intake, post-training, 6-month follow up, and 12-month follow up. There is also an optional interview about experiences of loneliness.

Sophia Vinogradov
Not specified
This study is NOT accepting healthy volunteers
STUDY00018733
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• aged 15-40 inclusive
• enrolled in an early psychosis coordinated specialty care clinic (PI will determine this)
• in good physical health & stable psychiatric status
• fluent in spoken and written English
• have access to a smart phone (or other mobile device) and computer or tablet
Exclusion Criteria:

• participated in significant cognitive training programs within the last three years
• neurological disorder that may interfere with participation
• substance abuse disorder that would interfere with participation
• risk of suicidal behavior
Brain & Nervous System, Mental Health & Addiction
Psychosis, schizoaffective disorder, schizophrenia
I'm interested
Share via email

MT2023-06: A CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF LERIGLITAZONE IN ADULT MALE SUBJECTS WITH CEREBRAL ADRENOLEUKODYSTROPHY (CALYX)

This study has 2 parts: a double-blind period and an open-label extension. In the double-blind period of this study, the study medicine will be compared to a placebo. A placebo is a treatment that looks and tastes exactly like the study medicine but does not contain any active ingredient. In this study, you will receive leriglitazone or placebo. Whether you receive leriglitazone or placebo will be decided randomly (by chance, like flipping a coin). In this study, 1 out of every 2 subjects (50%) will receive leriglitazone and 1 out of every 2 subjects (50%) will receive placebo. To make this study fair, you and the study doctor will not be told which treatment you will receive, this is called “blinding”. In the open-label extension, all subjects will receive leriglitazone.

Troy Lund
18 years and over
This study is NOT accepting healthy volunteers
SITE00001908
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosis of progressive cerebral adrenoleukodystrophy (cALD), defined as GdE with brain lesions
• bone marrow transplantation (HSCT) is not recommended patient is not willing to undergo HSCT
• no major cognitive impairment
• see link to clinicaltrials.gov for additional inclusion criteria
Exclusion Criteria:

• or treatment with ex-vivo gene therapy (eli-Cel).
• known type 1 or type 2 diabetes
• see link to clinicaltrials.gov for additional exclusion criteria
Rare Diseases
Clinics and Surgery Center (CSC), CEREBRAL ADRENOLEUKODYSTROPHY, cALD
I'm interested
Share via email
See this study on ClinicalTrials.gov

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

The primary objective for this observational study is to collect general and medical data from children, adolescents, and young adults who had pediatric onset rheumatic disease. This data will be used to evaluate the long-term safety and efficacy of therapeutic agents used to treat these diseases. This information will allow investigators to accurately report and follow changes in current medication use patterns and compare these to proposed standards and current treatment recommendations. The use of a single registry will allow for more analysis of the different therapeutic agents by allowing them to be compared to each other.

Colleen Correll
Not specified
This study is NOT accepting healthy volunteers
1506M74443
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosed with rheumatic disease prior to age 16 years for juvenile idiopathic arthritis (JIA)
• onset prior to age 19 years for all other rheumatic diseases
• younger than 21 years
Arthritis & Rheumatic Diseases, Cancer
juvenile idiopathic arthritis (JIA), pediatric rheumatic disease
I'm interested
Share via email
See this study on ClinicalTrials.gov

DegenPRO: A multicenter prospective registry for the management of degenerative spine disorders

This registry will be used to gather specific information about patients diagnosed with a degenerative spine disorder. Patient registries are observational studies that focus on understanding how the treatments, tests, and services, that are used in routine clinical care and by specialists, affect patient health outcomes. A registry that is appropriately designed, conducted, and analyzed will provide unique scientific information about the effectiveness, safety, and quality of the health-care service or intervention that is being studied.

Christopher Martin
18 years and over
This study is NOT accepting healthy volunteers
STUDY00000102
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosed with a degenerative spine disorder and receiving treatment
Bone, Joint & Muscle
Clinics and Surgery Center (CSC), Degenerative Diseases, Spinal Cord
I'm interested
Share via email
See this study on ClinicalTrials.gov

The Organ Care System (OCS) Lung Thoracic Organ Perfusion (TOP) Post Approval Study (PAS) Registry - OCS Lung TOP PAS Registry (TOP)

To collect additional real-world safety and effectiveness data for the OCS™ Lung System and to expand the long-term clinical evidence supporting the use of OCS™Lung System in lung transplantation.

Stephen Huddleston
18 years and over
This study is NOT accepting healthy volunteers
STUDY00003837
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• people who received OCS preserved double lung transplants
• OR people who receive a single lung transplant from OCS preserved lung pairs from either standard criteria donors
• AND all donor lungs that were perfused on OCS Lung System
Brain & Nervous System
Clinics and Surgery Center (CSC), Lung Transplant
I'm interested
Share via email
See this study on ClinicalTrials.gov

The (IRAD) International Registry for Acute Aortic Dissection (CCMOCPAAD)

The International Registry of Aortic Dissection (IRAD) was created in 1996 by cardiovascular specialists committed to expanding current knowledge of aortic dissection with the goal of improving patient outcomes. This registry study uses a standardized form to capture data from consecutive patients with aortic dissection at participating hospitals.

Stephen Huddleston
18 years and over
This study is NOT accepting healthy volunteers
1111M06641
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 18 to 80 years of age
• clinical diagnosis of acute aortic dissection
• Type A dissection
• Type B dissection
• Retrograde type B dissection
Exclusion Criteria:

• Aortic aneurysm
• Myocardial infarction
• Cerebral accident
• Active infection
Heart & Vascular
Aortic Dissection
I'm interested
Share via email
See this study on ClinicalTrials.gov

National Pediatric Cardiology Quality Improvement Collaborative (NPC-QIC) - A Collaborative Initiative to Improve Care of Children with Complex Congenital Heart Disease (NPC-QIC)

This study is being sponsored by the National Pediatric Cardiology Quality Improvement Collaborative (NPC-QIC). We want to learn more about improving the treatment and outcomes for patients who have a diagnosis of a single ventricle, such as Hypoplastic Left Heart Syndrome (HLHS) or similar heart defects.

Kavisha Shah
Up to 18 years old
This study is NOT accepting healthy volunteers
STUDY00004329
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• up to 15 months old
• newborns diagnosed with HLHS or other univentricular condition
• intended to undergo Norwood procedure
Children's Health, Heart & Vascular
Hypoplastic Left Heart Syndrome (HLHS)
I'm interested
Share via email
See this study on ClinicalTrials.gov

D2D Care Aware: Understanding Opioids in Minnesota

According to the Minnesota Department of Human Services, about 290,000 adults in Minnesota need treatment for addiction. National data suggests that only 10% of those who need treatment receive it. The goal of the study is to determine public opinion and knowledge about opioid use disorder and its treatment.

Robert Levy
18 years and over
This study is also accepting healthy volunteers
STUDY00022191
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Minnesota resident
Community Health, Mental Health & Addiction
addiction, opioid use disorder, substance use disorder, D2D
I'm interested
Share via email

CMRR Healthy Participant Registry

The purpose of this Health Participant Registry is to collect the names, contact information and answers to safety screening questions that assist in the determination of magnetic resonance (MR) compatibility of individuals who have expressed interest in MR research.

Jeramy Kulesa
18 years and over
This study is also accepting healthy volunteers
00015977
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 18 years old
• English speaking
• able to have a MRI scan, must complete assessment
Exclusion Criteria:

• women who are pregnant
Imaging, MRI
Visit study website
I'm interested
Share via email

ELEVATE, a global observational longitudinal prospective registry of patients with acute hepatic porphyria (AHP) (ELEVATE)

This is a global, multicenter, prospective, observational, longitudinal registry conducted to characterize the natural history and real-world clinical management of patients diagnosed with AHP. This protocol will not recommend the use of any specific treatments, visits, or procedures. No medication is provided as part of registry participation.

Gregory Vercellotti
This study is NOT accepting healthy volunteers
SITE00001194
Digestive & Liver Health, Rare Diseases
Clinics and Surgery Center (CSC)
I'm interested
Share via email
See this study on ClinicalTrials.gov

Improving Diagnosis and Treatment in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

This is a multi-center, prospective, observational cohort registry study looking at kids and their relatives with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).

Bradley Clark
Not specified
This study is NOT accepting healthy volunteers
STUDY00011733
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• anyone diagnosed with CPVT before 19 years of age.
Exclusion Criteria:

• significant medical history that isn't related to CPVT
Rare Diseases, Heart & Vascular
CPVT, arrhythmia, ventricular tachycardia
I'm interested
Share via email

Corrona Inflammatory Bowel Disease (IBD) Registry

This is a prospective, non-interventional, research study for patients with IBD under the care of a certified gastroenterologist. The primary objective for this registry is to prospectively study the natural history of IBD, the prevalence and incidence of comorbidities, targeted adverse events, and more, via questionnaires.

Eugenia Shmidt
18 years and over
This study is NOT accepting healthy volunteers
STUDY00007736
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 18 years old
• Diagnosis of one of the following by a gastroenterologist: Crohn's disease or Ulcerative colitis (UC)
• users of an approved biologic drug or JAK inhibitor (Tofacitinib) for the treatment of UC or Crohn's disease
Exclusion Criteria:

• Participating in or planning to participate in a clinical trial studying new medications for Crohn's disease or Ulcerative colitis
Digestive & Liver Health
Clinics and Surgery Center (CSC), Crohn's disease, Ulcerative colitis
I'm interested
Share via email
See this study on ClinicalTrials.gov

Global Patient Registry of Inherited Retinal Diseases

The purpose of this research study is to collect timely and relevant data that will support the evolving research needs of the Inherited Retinal Disease community (IRD), in order to provide insights that can be used to improve patient management, and to inform development of future treatments. No visits, assessments, or procedures are mandated, and follow-up will be captured as part of your standard of care. The planned length of registry is of 8 years with a potential to extend the duration as needs evolve.

Sandra Montezuma
Not specified
SITE00001950
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 3 years old
• documented genetic diagnosis of X-linked retinitis pigmentosa (XLRP) or Achromatopsia (ACHM) with any signs or symptoms of disease
• Caregiver participants must be at least 18 years old and identified by the participant as the primary care giver
Exclusion Criteria:

• received a treatment in an Inherited Retinal Disease (IRD) related interventional trial, or is being screened for an IIRD-related interventional trial
• Caregiver participant has an IRD and has visual impairment
Children's Health, Vision & Eyes
I'm interested
Share via email

Focus in NeuroDevelopment (FIND) Network: A Statewide Network for Research in Neurodevelopment

The purpose of this research project is to develop a registry and database of families with neurodevelopmental disorders.

Amy Esler
Not specified
This study is also accepting healthy volunteers
1306M35301
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• All ages
• All individuals with disabilities and families within the neurodevelopmental disorder community
• Also looking for clinicians, educators, and professionals in the field
Children's Health, Mental Health & Addiction
autism, OCD, ADHD, tic disorders, neurodevelopment, community outreach
I'm interested
Share via email

Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry (IPF/ILD-PRO)

Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life of IPF participants, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) established at the enrolling centers. In addition, blood samples will be collected and banked for future research projects.

Hyun Kim
18 years and over
This study is NOT accepting healthy volunteers
1408M52921
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 30 years old
• new diagnosis of Idiopathic Pulmonary Fibrosis (IPF) -diagnosis of a non-IPF Interstitial Lung Disease (ILD) of any duration, including, but not limited to Idiopathic Non-Specific Interstitial, Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis
Exclusion Criteria:

• Cancer, treated or untreated, other than skin or early stage prostate cancer, within the past 5 years
• currently waiting for lung transplantation
• currently enrolled in a clinical trial
Respiratory System
Clinics and Surgery Center (CSC), Idiopathic Pulmonary Fibrosis (IPF) Interstitial Lung Disease
I'm interested
Share via email
See this study on ClinicalTrials.gov

Monoclonal Gammopathy and Amyloidosis Registry and Biobank (MGARB)

The purpose of this study is to establish a registry and biobank to study monoclonal gammopathy and amyloidosis. We aim to understand better the changes these diseases cause, the symptoms they present, and the clinical progression to be able to better prevent them and treat them in the future.

Sabine Karam
18 years and over
This study is NOT accepting healthy volunteers
STUDY00018498
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosis of monoclonal gammopathy or amyloidosis
Exclusion Criteria:

• unable to speak English
Rare Diseases
Clinics and Surgery Center (CSC), amyloidosis, monoclonal gammopathy
I'm interested
Share via email

Cardiac Sarcoidosis Consortium

This is a registry study. The Cardiac Sarcoidosis Consortium (CSC) is an international, multicenter partnership among physicians and allied professionals at major medical centers with the unifying purpose to learn more about cardiac sarcoidosis through collaborative research.

Henri Roukoz
18 years and over
This study is NOT accepting healthy volunteers
1209M20465
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• People who have been diagnosed with Cardiac sarcoidosis (CS)
• History of ventricular tachycardia or fibrillation
• Ventricular arrhythmias treated medically or with an implanted device
Heart & Vascular
Ventricular Tachycardia, Cardiac sarcoidosis, ablation, cardiac ablation, Clinics and Surgery Center (CSC)
I'm interested
Share via email

COG APEC14B1 The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study Additional Title: EVERYCHILD (APEC14B1) PCR - COG Foundation

This research trial studies the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

Brenda Weigel, MD, MSc
Not specified
This study is NOT accepting healthy volunteers
SITE00000151
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• must be =< 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network [NCTN]) therapeutic study, for which there is a higher upper age limit
• patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations
• enrollment must occur within 6 months of initial disease presentation OR within 6 months of refractory disease, disease progression, disease recurrence, second or secondary malignancy
• see link to clinicaltrials.gov for additional inclusion criteria
Cancer
childhood cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov

ALX-HPP-501: An Observational,Longitudinal Prospective, Long-term Registry of Patients with Hypophosphatasia

This is a long-term registry is designed to collect data on hypophosphatasia (HPP) to better understand the condition and learn more about the disease, how patients feel about living with HPP and effect of HPP on the patients wellbeing and health. The study will look at participant’s medical records and health questionnaires about the health status of patients. This study collects observational data from clinical care and does not involve any treatment for HPP or administration of medication for HPP.

Kyriakie Sarafoglou
Not specified
This study is NOT accepting healthy volunteers
STUDY00004936
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• confirmed diagnosis of HPP.
• documented alkaline phosphatase (ALP) activity below the lower limit of normal for age and sex, or a documented ALPL gene mutation.
• able to read and speak English
Exclusion Criteria:

• currently participating in an Alexion-sponsored clinical trial
Rare Diseases
HPP, Hypophosphatasia
I'm interested
Share via email
See this study on ClinicalTrials.gov

Impact of Inflammatory Bowel Disease and IBD-related Surgery on Female Fertility: A Prospective Registry

This is a prospective questionnaire study that will examine the impact of IBD and its surgical treatments on fertility in women with IBD of reproductive age (18-45). Women with IBD who are attempting to get pregnant within the next year will answer questionnaires about their general, surgical and reproductive health, conception history and sexual partner information. This will help identify risk factors predictive of fertility outcomes and early fetal loss, determine time to conception, and assess efficacy of fertility services including in vitro fertilization.

Eugenia Shmidt
18 years and over
This study is NOT accepting healthy volunteers
STUDY00003958
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• age 18-45 years
• diagnosis of inflammatory bowel disease (IBD)
• not currently pregnant or trying to get pregnant
• desire to become pregnant within the next 12 months (may become pregnant while in the study)
Exclusion Criteria:

• prior pelvic surgery, including surgery of the cervix, ovary, uterus or fallopian tubes
• known female sterility
• known male infertility factors in partner
Digestive & Liver Health, Women's Health
Fertility, IBD, Inflammatory Bowel Disease
I'm interested
Share via email

Muscular Dystrophy Association Neuromuscular Observational Research (MOVR) Data Hub Protocol (#MDACS1)

The Muscular Dystrophy Association (MDA) wants to collect information about individuals with neuromuscular disease to better understand the disease progression and ultimately improve the medical care, quality of life, and survival of those with neuromuscular disease. To collect this information, MDA has created a data registry called the Neuromuscular Observational Research Data Hub (referred to as the “MOVR Data Hub”).

Peter Karachunski
Not specified
This study is NOT accepting healthy volunteers
SITE00000485
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Any person who has a diagnosis of ALS, DMD, BMD, SMA, or any other neuromuscular diseases
Exclusion Criteria:
There are no exclusion criteria
Brain & Nervous System
Muscular Dystrophy, Neuromuscular diseases, Muscular Dystrophy Association (MDA)
I'm interested
Share via email

Syn-Sleep Study

The purpose of the study is to evaluate the use of the Syn-One Test for identifying patients with idiopathic rapid eye movement sleep disorder (iRBD) that will progress to synucleinopathies, such as Parkinson’s disease, dementia with Lewy bodies, pure autonomic failure and multiple system atrophy. Your participation will last approximately 2 years.

Michael Howell
18 years and over
This study is NOT accepting healthy volunteers
STUDY00020941
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• age 18 to 65
• diagnosis of Rapid Eye Movement (RBD) sleep disorder
• have repeated episodes of sleep related vocalizations and/or complex motor behaviors
• documented by sleep study to occur during REM sleep
Exclusion Criteria:

• diagnosis of Parkinson's disease, dementia, multiple system atrophy or any other cause
• unable to have a skin biopsy because of poor wound healing, use of anticoagulants other than aspirin or Plavix, or severe vascular disease
Rare Diseases
RBD, REM, REM Sleep Behavior Disorder (iRBD), Sleep
I'm interested
Share via email

The DART Study

We are interested in learning more about how Transcranial Magnetic Stimulation (TMS) and ketamine affect depressive symptoms. We are most interested in learning how anhedonia (lacking pleasure in life) is changed by these treatments. Patients who have been diagnosed with treatment-resistant depression (TRD) and who are also scheduled to receive ketamine or Transcranial Magnetic Stimulation (TMS) are being recruited for this study. We are looking to enroll a second group of participants into a healthy control group who have not been diagnosed with a psychiatric disorder. This group will have a single 60 minute visit in which computer tasks and surveys will be completed while wearing an electroencephalogram (EEG) head cap to record brain activity.

Alexander Herman
18 years and over
This study is also accepting healthy volunteers
STUDY00013617
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• criteria for healthy volunteers: age 18 or older and able to read English
Exclusion Criteria:

• diagnosis or history of depression, bipolar disorder, Generalized Anxiety Disorder, or other psychiatric conditions.
Mental Health & Addiction
Depression, EEG, TMS, Treatment Resistant Depression
I'm interested
Share via email

Liver Collection Study

This is a study of individuals older than 18, undergoing abdominal procedures in which the liver is accessible, and are amenable to liver samples being collected during their surgical procedure, with the option to participate in a specialized scan that can provide information on liver health, stiffness, and fat content. This study is trying to figure out how senescent (aging) cells in the liver are related to an individual's health status and better understand the association between these cells and different metabolic diseases.

Sayeed Ikramuddin
18 years and over
This study is NOT accepting healthy volunteers
STUDY00013764
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Age 18 years or older
• Undergoing abdominal surgical procedure with general anesthesia
Exclusion Criteria:

• Pregnancy or nursing
• Physician may exclude
Diabetes & Endocrine, Digestive & Liver Health, Prevention & Wellness
abdominal surgery, liver biopsy
I'm interested
Share via email

Chilled Platelet Study (CHIPS)

The purpose of this research study is to compare the transfusion of cold-stored (refrigerated) platelets to standard room temperature stored platelets. The goal of the trial is to determine whether platelets stored cold are similar or better at stopping bleeding compared to platelets stored at room temperature and, if so, to determine the maximum duration of cold storage that maintains a similar effect on bleeding

Claudia Cohn
Not specified
This study is NOT accepting healthy volunteers
SITE00001231
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• age greater than 28 days and less than 85 years
• planned complex cardiac surgery with planned use of cardiopulmonary bypass
Exclusion Criteria:

• known or suspected pregnancy
• conscious objection or unwillingness to receive blood products
• known congenital platelet disorder or bleeding disorder
• additional exclusion criteria (study staff will review)
Heart & Vascular
CABG, cardiac surgery, cardiopulmonary bypass
I'm interested
Share via email
See this study on ClinicalTrials.gov

Ten Thousand Families Study

The purpose of this study is to study the evolution of early life risk factors that may lead to cancer and other conditions. This is a prospective cohort study of families who reside in Minnesota.

Jen Poynter
Not specified
This study is also accepting healthy volunteers
STUDY00000877
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 1st Participant: 18+ living in MN
• Other family members: All ages and must live in MN, ND, SD, IA, or WI
• Participants ages 0-17 must have a parent consent to their participation and assist with study activities
Exclusion Criteria:

• Unwilling or unable to provide DNA and blood sample
• Does not have at least 1 living family member in MN IA, ND, SD, or WI
Cancer, Microbiota, Prevention & Wellness
Minnesota, PFAS, environment, exposures, family, genetics, glyphosate, lifestyle, radon, 10KFS, D2D
Visit study website
I'm interested
Share via email

Longitudinal Study of Porphyrias

The objective is to conduct a longitudinal investigation of the natural history, complications, and therapeutic outcomes in people with acute and cutaneous porphyria.

Marshall Mazepa, MD
Not specified
This study is NOT accepting healthy volunteers
SITE00000892
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• patient of any age
• diagnosis of a porphyria
• biochemical findings, as documented by laboratory reports of porphyria-specific testing performed after 1980
Exclusion Criteria:

• elevations of porphyrins in urine, plasma or erythrocytes due to other diseases
Rare Diseases
Acute Porphyrias, Cutaneous Porphyrias
I'm interested
Share via email
See this study on ClinicalTrials.gov